The Fulham Shore Share Discussion Threads

[kph] 29/1/2009 11:42

ansc the 50000 yesterday was mine and it was a buy, good luck all holders!!

[ansc] 28/1/2009 16:12

With two of the non-execs willing to pay 3.5p as recently as 24 November last year, the same price as FUL's FD has topped-up on numerous occasions during the last couple of years, I'm surprised that some investors want out at around a measly 2p. My desire to add to my pot, therefore, was made possible yesterday at a very acceptable 2.35p.

'A fool and his money ......' as the saying goes!

[ansc] 08/1/2009 17:12

Sale after sale has been recorded during the past six weeks but the MMs steadfastly refuse to drop their offer price below the 3.00p level. Why? Has someone warned them that I'm looking to add but not pay more than 2.75p?!

Oh well, I suspect there's plenty more 'selling' water to flow under this particular bridge yet so there's no rush......

[welsheagle] 06/12/2008 19:48

From November's 'Company Refs', when price was 2.38p:-
a/ Prospective PE ratio of 3.65 (based on one broker forecast, recommending 'buy').
b/ Price to sales ratio of 0.18.
c/ Net asset value per share of 3.19p.
d/ Net cash per share of 0.41.
e/ Negative gearing of 8.52%.
f/ One director buying recently.
g/ Turnover up from £7.81m to £19.2m in last five years.
h/ Positive cash flow of 0.58p per share.
i/ Forecast growth in eps of 99.3%.

[pennstreet] 24/11/2008 13:07

Nice juicy director buys !

[pennstreet] 14/11/2008 13:22

Another nice purchase !

[pennstreet] 13/11/2008 13:50

Nice purchase

[pennstreet] 12/11/2008 09:58

Not much buying volume ?

[garth] 12/11/2008 07:21

Well, on the basis of those results I'm very happy to have added recently - sorry to have not bought more. EPS of .18p puts them on a pe 11-12 and the positive cash generation means that they are currently trading at less than cash levels...... That stacks up to too low a valuation IMO.

G.

[platts] 08/11/2008 18:13

So did I (via techinvest) and also bought more.
My advice: it is far too late to sell. Get a life, forget about the stock and maybe one day (impossible to predict) something will happen- don't buy any more whatever you do. (go for gold stocks)

[gimeabreak] 07/11/2008 21:51

I first bought shares into Fulcrum in January 2002 @19.5p and have purchased more stock a couple of times a year since I just wondering if I'm going to lose it all the situation looks pretty dire to me

[yogro] 04/10/2008 05:49

Message for Bob P....Message for Bob P long time no Uranian.

Dear Bob,
Your Rocket ship waits on the tarmac, please take your seat and complimentary gift. (Revell scale 1/100 model plastic Porsche).

Everyone else, beware the Uranian fiend from outer space.

[bbd2] 02/10/2008 17:47

Their website is certainly looking much more professional:

[cockneyrebel] 26/9/2008 10:10

A couple of interesting new non-execs joining.

Add that to the director buying and it looks interesting.

CR

[ansc] 13/9/2008 08:23

I think I have to side with squaddie's interpretation of yesterday's announcement. I have yet to meet a director who willingly buys his company's shares knowing that there's a strong chance of the price dropping back afterwards. On the other hand, I've witnessed one or two ducking for the exit a few weeks prior to a setback being announced and the price crashing, it's human nature after all no matter what the regulations stipulate. Whatever the reason, at least it's another 1.7 mil shares parked in safe hands which the MMs can't use now in their favourite pastime of manipulating the sp!

What bugs me, however, is that on the transaction date (10th), no deals were marked at the stated RNS price of 3.6p. There were some weird and wonderful figures recorded on that date but none of them add up to neat round 1.7 mil. As if life wasn't tough enough for IPs without duff transaction information as an additional hindrance.

[squaddie] 12/9/2008 13:12

buggy. As directors of a company they know well before the actual results are published if the comany is doing well or not. And as long as the shares are purchased outside of the prohibited period, which in this case they have been, then no insider dealing can be claimed. All directors buy based on previllaged information, ageed not all directors buys are good ones, but with three buying at the same time it does I feel bode well.

[buggy] 12/9/2008 12:58

squaddie,

I see it a bit differently. Directors will not have bought if the results are anything spectacular.

That would be insider dealing if they acted on any previllaged information they may have obtained due to their position in the company.

I think this buy may just be a rallying the troops call. ...."...... I know it does not look too good now but I am very confident that the worst is behind us .." kind of buy.

[squaddie] 12/9/2008 12:51

Intersting time for directors to be buying. Results to the end of august ?. Directors would not have bought if it was known that the results would be anything other than excellent.

[cockneyrebel] 12/9/2008 12:23

Seen the director buying today?

New CEO, new chairman, new growth strategy, directors buying - looks like a good recipe imo.

CR

[platts] 10/9/2008 11:52

the fundamentals of the stock are quite good- pity there is a bear market around.

[ansc] 10/9/2008 10:26

It looks as though someone's got cash to play with judging by that buy yet the share price hasn't budged. Rollover?

[bbd2] 03/9/2008 09:35

That is quite a pedigree and one with financial connections that should prove useful in getting FUL's name known among the City movers and shakers.

We have always been ignored by the city in the past, hopefully this is the start of a new era.

[ansc] 02/9/2008 20:14

Will Sir Charles be retiring after delivering good news in his last results announcement, I sincerely hope so. I'm slightly puzzled as to the need for another chartered accountant on the Board though:

FULCRUM PHARMA PLC ("the Company") - 2 September 2008

Appointment of Non-executive Director and Chairman Designate

The Board of Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services company, is pleased to announce that Grahame Cook has joined the board as a Non-executive Director and Chairman designate. It is planned that Sir Charles George will retire as Chairman and from the Board at the Annual General Meeting in December 2008.

Commenting on these changes to the Board, Dr Frank Armstrong, CEO of Fulcrum Pharma, said, "I would like to thank Sir Charles for his 8 years of leadership of the Board of Fulcrum Pharma. Sir Charles has been a dedicated and involved Chairman who has given great service to the Company. Looking forward, I am delighted to welcome Grahame Cook to the Board in the role of Chairman designate. As we look to grow and develop the business Grahame's background and skills will be invaluable."

Commenting on his appointment Mr. Cook said, "I am pleased to join the Board of Fulcrum Pharma at an exciting time of change for the company and the Pharma and Biotechnology industry as a whole. I am convinced of the opportunity Fulcrum Pharma has to become a substantial professional services company."

Mr. Cook, aged 50, a chartered accountant, has held a number of senior executive positions including, most recently his role as Chief Executive at WestLB Panmure, until 2003, where he was responsible for all global functions and the expansion and development of WestLB Panmure's business. Prior to this he spent three years at UBS as a managing director where he was on the Global Investment Banking Management Committee. He was also a director of Barclays de Zoete Wedd. He was a founding member of the London Stock Exchange techMARK Advisory Council and currently holds various other non-executive positions including Antisoma PLC, Sinclair Pharma Plc and Minoan Group plc.